Voss Capital, LP has reported the acquisition of common shares of Rein Therapeutics Inc. (RNTX), according to a recent SEC filing. The form was filed by more than one reporting person, including Voss Capital, LP and Voss Value Master Fund, L.P., among other reporting beneficial owners. The full filing can be accessed through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000921895-25-002819), on October 28, 2025, and is solely responsible for the information contained therein.